Please login to the form below

Not currently logged in
Email:
Password:

S-A enters research deal with Stanford

Sanofi-aventis has entered into a research collaboration with Stanford University that is aimed at early-stage science

Sanofi-aventis (S-A) has entered into a research collaboration with Stanford University that is aimed at early-stage science.

The multi-year partnership allows the company to work with Stanford's Bio-X interdisciplinary life sciences research programme, which "supports, organises, and facilitates interdisciplinary, collaborative and innovative research projects in the early phases of development." The partners will work together on up to five projects a year, funded by a Joint Steering Committee.

Other elements of the collaboration include the opportunity for S-A to host postdoctoral fellows at the company and for company researchers to be invited by Stanford faculty to be visiting scholars and to pursue research collaborations at the university.

Each year, S-A will fund a research forum to allow company researchers and Stanford scientists to come together to share knowledge and ideas, as well as to discuss the projects under development.

Bio-X is a joint project of Stanford's Schools of Humanities and Sciences, Engineering, Earth Sciences and Medicine that was formed in 1998 to promote interdisciplinary research in the biosciences.

The programme has 450 affiliated faculty from 50 academic departments at the university, including biology/life sciences, engineering, computer science, clinicians/clinical research, law/ethics/mathematics/statistics and physical sciences.

"The results so far have included numerous biomedical inventions and life science discoveries that have expanded our understanding of the human body and how to treat disease," Stanford said of the programme. "But this is only the beginning: Bio-X is an experiment in progress. The achievements to date are in some sense a 'proof of principle' of even greater undertakings to come."

The collaboration follows news in January that S-A would partner with the University of California, San Francisco (UCSF), in areas including oncology, diabetes and ageing.

The company had previously announced it would partner with Harvard University on translational biomedical research in several therapeutic areas, including oncology and diabetes.

19th April 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...

Infographics